Literature DB >> 24951958

β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes.

Jaime García-Prieto1, Jose Manuel García-Ruiz, David Sanz-Rosa, Andrés Pun, Ana García-Alvarez, Sean M Davidson, Leticia Fernández-Friera, Mario Nuno-Ayala, Rodrigo Fernández-Jiménez, Juan A Bernal, José Luis Izquierdo-Garcia, Jesús Jimenez-Borreguero, Gonzalo Pizarro, Jesús Ruiz-Cabello, Carlos Macaya, Valentín Fuster, Derek M Yellon, Borja Ibanez.   

Abstract

Selective stimulation of β3 adrenergic-receptor (β3AR) has been shown to reduce infarct size in a mouse model of myocardial ischemia/reperfusion. However, its functional long-term effect and the cardioprotective mechanisms at the level of cardiomyocytes have not been elucidated, and the impact of β3AR stimulation has not been evaluated in a more translational large animal model. This study aimed at evaluating pre-perfusion administration of BRL37344 both in small and large animal models of myocardial ischemia/reperfusion. Pre-reperfusion administration of the β3AR agonist BRL37344 (5 μg/kg) reduced infarct size at 2-and 24-h reperfusion in wild-type mice. Long-term (12-weeks) left ventricular (LV) function assessed by echocardiography and cardiac magnetic resonance (CMR) was significantly improved in β3AR agonist-treated mice. Incubation with β3AR agonist (BRL37344, 7 μmol/L) significantly reduced cell death in isolated adult mouse cardiomyocytes during hypoxia/reoxygenation and decreased susceptibility to deleterious opening of the mitochondrial permeability transition pore (mPTP), via a mechanism dependent on the Akt-NO signaling pathway. Pre-reperfusion BRL37344 administration had no effect on infarct size in cyclophilin-D KO mice, further implicating mPTP in the mechanism of protection. Large-white pigs underwent percutaneous coronary ischemia/reperfusion and 3-T CMR at 7 and 45 days post-infarction. Pre-perfusion administration of BRL37344 (5 μg/kg) decreased infarct size and improved long-term LV contractile function. A single-dose administration of β3AR agonist before reperfusion decreased infarct size and resulted in a consistent and long-term improvement in cardiac function, both in small and large animal models of myocardial ischemia/reperfusion. This protection appears to be executed through inhibition of mPTP opening in cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24951958     DOI: 10.1007/s00395-014-0422-0

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  26 in total

Review 1.  Upregulation of β3-adrenoceptors-a general marker of and protective mechanism against hypoxia?

Authors:  Massimo Dal Monte; Bronwyn A Evans; Ebru Arioglu-Inan; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

2.  A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics.

Authors:  Fernando García-Marqués; Marco Trevisan-Herraz; Sara Martínez-Martínez; Emilio Camafeita; Inmaculada Jorge; Juan Antonio Lopez; Nerea Méndez-Barbero; Simón Méndez-Ferrer; Miguel Angel Del Pozo; Borja Ibáñez; Vicente Andrés; Francisco Sánchez-Madrid; Juan Miguel Redondo; Elena Bonzon-Kulichenko; Jesús Vázquez
Journal:  Mol Cell Proteomics       Date:  2016-02-18       Impact factor: 5.911

3.  Peoniflorin Preconditioning Protects Against Myocardial Ischemia/Reperfusion Injury Through Inhibiting Myocardial Apoptosis: RISK Pathway Involved.

Authors:  Hongen Ma; Jiping Hao; Huihui Liu; Jia Yin; Mingmin Qiang; Meilin Liu; Shaohui He; Di Zeng; Xiongtao Liu; Cheng Lian; Yuqin Gao
Journal:  Appl Biochem Biotechnol       Date:  2021-10-01       Impact factor: 2.926

4.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

5.  Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction.

Authors:  Xavier Rossello; Antonio Piñero; Rodrigo Fernández-Jiménez; Javier Sánchez-González; Gonzalo Pizarro; Carlos Galán-Arriola; Manuel Lobo-Gonzalez; Jean Paul Vilchez; Jaime García-Prieto; Jose Manuel García-Ruiz; Ana García-Álvarez; David Sanz-Rosa; Borja Ibanez
Journal:  J Cardiovasc Transl Res       Date:  2018-08-02       Impact factor: 4.132

6.  β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling.

Authors:  Alessandro Cannavo; Giuseppe Rengo; Daniela Liccardo; Andres Pun; Ehre Gao; Alvin J George; Giuseppina Gambino; Antonio Rapacciuolo; Dario Leosco; Borja Ibanez; Nicola Ferrara; Nazareno Paolocci; Walter J Koch
Journal:  J Am Coll Cardiol       Date:  2017-07-11       Impact factor: 24.094

7.  Optimization of dual-saturation single bolus acquisition for quantitative cardiac perfusion and myocardial blood flow maps.

Authors:  Javier Sánchez-González; Rodrigo Fernandez-Jiménez; Nils D Nothnagel; Gonzalo López-Martín; Valentin Fuster; Borja Ibañez
Journal:  J Cardiovasc Magn Reson       Date:  2015-02-19       Impact factor: 5.364

8.  Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.

Authors:  Ana García-Álvarez; Daniel Pereda; Inés García-Lunar; David Sanz-Rosa; Rodrigo Fernández-Jiménez; Jaime García-Prieto; Mario Nuño-Ayala; Federico Sierra; Evelyn Santiago; Elena Sandoval; Paula Campelos; Jaume Agüero; Gonzalo Pizarro; Víctor I Peinado; Leticia Fernández-Friera; José M García-Ruiz; Joan A Barberá; Manuel Castellá; Manel Sabaté; Valentín Fuster; Borja Ibañez
Journal:  Basic Res Cardiol       Date:  2016-06-21       Impact factor: 17.165

Review 9.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  Exogenous Administration of Recombinant MIF at Physiological Concentrations Failed to Attenuate Infarct Size in a Langendorff Perfused Isolated Mouse Heart Model.

Authors:  Xavier Rossello; Niall Burke; Christian Stoppe; Jurgen Bernhagen; Sean M Davidson; Derek M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  2016-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.